Given the established role of CD99 in leukocyte migration and T-cell activation, developing strategies that reduce lymphocyte diapedesis and subsequent inflammation in the IBD microenvironment using anti-CD99 may be a useful approach. The gene discussed is CD99; the disease is inflammatory bowel disease.